DEA Bans Risky Synthetic Drug MDMB-4en-PINACA Immediately
Published Date: 4/24/2026
Rule
Summary
Starting April 27, 2026, the DEA is officially putting MDMB-4en-PINACA—a powerful and risky chemical—into Schedule I, the strictest drug category. This means anyone making, selling, or using it will face serious legal rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer from this dangerous substance.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
MDMB-4en-PINACA placed in Schedule I
On April 27, 2026, the Drug Enforcement Administration permanently placed MDMB-4en-PINACA (including its salts and isomers) in Schedule I of the Controlled Substances Act. That means manufacture, distribution, import/export, research, or possession of MDMB-4en-PINACA without proper authorization is subject to Schedule I regulatory controls and administrative, civil, and criminal sanctions.
DEA Registration and Compliance Required
Anyone who handles MDMB-4en-PINACA (manufacture, distribute, import/export, research, chemical analysis, or possession) must register with DEA and comply with Schedule I rules starting April 27, 2026. Registered handlers must follow specific controls including security, labeling and packaging rules, quota limits, order form requirements, and recordkeeping and reporting obligations; inventories are required initially when first handling and then at least every two years.
Research Allowed With Schedule I Registration
Placement in Schedule I does not prohibit bona fide research on MDMB-4en-PINACA, but researchers must apply for and obtain Schedule I researcher registration through DEA's researcher registration program to conduct such work. The rule notes researchers wishing to study Schedule I substances may apply for permission under the schedule I researcher registration process.
DEA Certifies Minimal Small-Entity Impact
DEA certified that this final rule will not have a significant economic impact on a substantial number of small entities. DEA stated it identified one supplier in relevant industries (already DEA-registered) and found no evidence of significant diversion from legitimate suppliers.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2026-08103, One-Page Document on Passenger Rights
Starting May 26, 2026, airlines must create and share a simple, one-page summary of passenger rights about delays, cancellations, baggage, and boarding. This info will be easy to find on airline websites within 90 days after official approval, helping travelers know what to expect and what they’re entitled to. This rule affects all covered airlines and aims to make flying less confusing and more fair—no extra cost to passengers, just clearer info!
Next: 2026-08106, Airworthiness Directives; Pratt & Whitney Engines
The FAA is rolling out new safety checks for certain Pratt & Whitney engines to catch cracks early and keep flights safe. Starting May 29, 2026, operators must perform regular ultrasonic inspections and replace parts if needed, preventing engine shutdowns like a recent scary incident. This means some extra work and costs but keeps everyone flying worry-free!